CC News Briefs

Radiobiological Parameters Could Help Improve Treatment Outcomes in CCA

Tumor volume and tumor absorbed dose are significant predictors of the time to tumor progression in intrahepatic cholangiocarcinoma (CCA), according to a new study by Italian researchers. According to first author Tommaso Depalo from the Regional Center of Nuclear Medicine at the University Hospital of Pisa in Italy and the coauthors of the study, knowing…

malignant tumor

Study Suggests Tan-IIA Could Help Treat Cholangiocarcinoma

Tanshinone IIA (Tan-IIA) suppresses the proliferation and migration of cholangiocarcinoma cells and induces their apoptosis, according to the findings of a new study published in Scientific Reports. “Our research provides a new anticancer strategy and strengthens support for the use of Tan-IIA as an anticancer drug for the treatment of [cholangiocarcinoma],” the authors wrote. Tan-IIA…

Genetic research

Potential New Biomarker for Extrahepatic Cholangiocarcinoma Identified

The expression of epithelial membrane protein 1 (EMP1) can help distinguish between patients with extrahepatic cholangiocarcinoma and healthy controls, according to the results of a new study published in The International Journal of Biological Markers. Moreover, low expression levels of the protein are indicative of an unfavorable prognosis. These findings suggest that EMP1 is a…

Cholangiocarcinoma Testing

New Preoperative Model Predicts Overall Survival Among iCC Patients

A new preoperative model with good predictive performance for overall survival among intrahepatic cholangiocarcinoma (iCC) patients was described in a recent study published in the Journal of Ultrasound in Medicine. The newly developed method by Li et al consisted of a preoperative nomogram integrated with an ultrasound-based signature of both radiomic and radiographic features. This…

IPF clinical trial

Clinical Trial Reports Benefit of Ivosidenib in Cholangiocarcinoma

Ivosidenib is well tolerated and leads to improved overall survival compared to placebo in advanced cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation, according to the results of a randomized phase 3 clinical trial published in JAMA Oncology. “These data, coupled with supportive quality of life data and a tolerable safety profile, demonstrate the…

woman prepares an IV Drip

Derazantinib Effective for Patients With Some Types of Cholangiocarcinoma

Derazantinib treatment is effective and leads to durable objective responses in patients with inoperable or advanced intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements, according to primary results from a phase 2 clinical trial called FIDES-01. These findings were presented on September 16, 2021, by Michele Droz Dit Busset, MD, at the European Society for…

ALGS genetics

New Predictive Model Differentiates Types of Primary Liver Cancer

A new predictive model presented virtually at the European Society for Medical Oncology (ESMO) Congress 2021 was able to detect primary liver cancer (PLC) and distinguish between hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The new study utilized plasma cell-free DNA (cfDNA) fragmentomic profiles and a machine learning model to differentiate patients with PLC from…

Cholangiocarcinoma differential diagnosis

Robotic Resection Safe, Feasible in Extrahepatic Cholangiocarcinoma

Robotic resection of extrahepatic cholangiocarcinoma (eCCA) is safe, feasible, and reproducible, according to a new study published in the Journal of Surgical Oncology. “Because surgical resection provides the only chance for cure in extrahepatic cholangiocarcinoma, improving the risk‐to‐benefit ratio in the operating room, as the robotic platform does via small incisions, allows more patients to…

Cholangiocarcinoma Etiology

Lymph Node Dissection Offers Therapeutic Benefits in Cholangiocarcinoma

Lymph node dissection (LND), or lymphadenectomy, has recently been shown to improve outcomes in patients with certain forms of intrahepatic cholangiocarcinoma (ICC). Patients who underwent LND had improved 1-, 3-, and 5-year survival rates (83.5%, 52.2%, and 42.8%, respectively), compared to those who did not receive LND, whose survival rates were of 1.9%, 32.4%, and…

Next post in CC News Briefs